CLPT vs. CNMD, CDRE, LQDA, INMD, PLSE, BLFS, AORT, MDXG, RXST, and FNA
Should you be buying ClearPoint Neuro stock or one of its competitors? The main competitors of ClearPoint Neuro include CONMED (CNMD), Cadre (CDRE), Liquidia (LQDA), InMode (INMD), Pulse Biosciences (PLSE), BioLife Solutions (BLFS), Artivion (AORT), MiMedx Group (MDXG), RxSight (RXST), and Paragon 28 (FNA). These companies are all part of the "medical equipment" industry.
ClearPoint Neuro vs.
ClearPoint Neuro (NASDAQ:CLPT) and CONMED (NYSE:CNMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability, community ranking and media sentiment.
In the previous week, ClearPoint Neuro and ClearPoint Neuro both had 5 articles in the media. CONMED's average media sentiment score of 0.84 beat ClearPoint Neuro's score of 0.18 indicating that CONMED is being referred to more favorably in the news media.
CONMED has a net margin of 10.13% compared to ClearPoint Neuro's net margin of -59.64%. CONMED's return on equity of 14.31% beat ClearPoint Neuro's return on equity.
ClearPoint Neuro has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, CONMED has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500.
ClearPoint Neuro presently has a consensus target price of $19.67, indicating a potential upside of 17.62%. CONMED has a consensus target price of $77.20, indicating a potential upside of 26.58%. Given CONMED's higher probable upside, analysts clearly believe CONMED is more favorable than ClearPoint Neuro.
CONMED received 12 more outperform votes than ClearPoint Neuro when rated by MarketBeat users. However, 88.89% of users gave ClearPoint Neuro an outperform vote while only 47.37% of users gave CONMED an outperform vote.
30.1% of ClearPoint Neuro shares are owned by institutional investors. 6.1% of ClearPoint Neuro shares are owned by insiders. Comparatively, 6.8% of CONMED shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
CONMED has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.
Summary
CONMED beats ClearPoint Neuro on 12 of the 16 factors compared between the two stocks.
Get ClearPoint Neuro News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLPT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ClearPoint Neuro Competitors List
Related Companies and Tools
This page (NASDAQ:CLPT) was last updated on 2/22/2025 by MarketBeat.com Staff
